精華白牌隱形眼鏡 日本市場第一!!

精華隱形眼鏡今年出貨衝4億片新高日本彩色片新客戶訂單到！鉅亨網　　2012-05-08精華(1565-TW)董事長陳明賢今天表示，精華光在日本隱形眼鏡代工市場，「白牌」品質超越嬌生，已做到讓日本客戶「心服口服」，第2家日本客戶訂單，可望自5月起交貨，精華在日本隱形眼鏡代工目前已躍居第1大，單月營收很快即可突破3億元門檻，今年全年隱形眼鏡出貨量將挑戰4億片新高！精華目前有34條生產線，每條產線產能約1000萬片，總產能為3.4億片，去年新購置的廠房，預定第3季完工，將有增加10條生產線的空間。不過陳明賢強調，精華的強項在於生產調度與「超產」，產能利用率將可超過100%，即使接獲客戶訂單後，再開始調度產線生產，均可如期交貨。陳明賢指出，精華光學去年在內銷部分，銷售量正式突破1億片，而其他4家進口隱形眼鏡廠，銷售量為1.58億片，內銷部分精華市占率已達39%，外銷部分，精華去年外銷達3.2億片，占整體外銷比重達84%。精華今年在彩色片部分，銷售量將可突破1億片，全球市占率排名第2，僅次於嬌生。去年精華市場以亞洲為主，亞洲占營收比重達47%，其中以日本為主，台灣占營收比重為36%，其中日拋型為日本、台灣銷售比重最高產品，歐洲、美洲各占14%、3%。陳明賢表示，精華未來將視訂單需求，擴充製程設備，而未來將繼續拓展彩色日拋隱形眼鏡的海外市場，並提供多樣化產品，滿足各地客戶市場區隔需求。精華4月營收為2.97億元，年增9.15%，為單月歷史次高記錄，法人指出，精華5月起在日本新客戶訂單到位後，業績將有機會更上層樓，最快第2季單月營收即有機會突破3億元大關。

台微體 新增董事: 康惠媚

台微體：公告本公司101年股東常會獨立董事候選人名單2012/5/8鉅亨網第三十四條　第39款1.事實發生日:101/05/082.公司名稱:台灣微脂體股份有限公司3.與公司關係(請輸入本公司或聯屬公司):本公司4.相互持股比例(若前項為本公司，請填不適用):不適用5.發生緣由:依據公司法第192條之1規定，公告本公司101年度股東常會獨立董事候選人名單6.因應措施:不適用7.其他應敘明事項:(1)本公司101年度股東常會獨立董事候選人提名期間:101/04/20~101/04/30(2)下列獨立董事被提名人之資格條件，業經本公司101年05月08日董事會審查通過，茲將提名資料公告如下:獨立董事候選人:康惠媚 學歷:國立台灣大學EMBA經歷:國票綜合證券股份有限公司總經理、寶來證券投資信託股份有限公司副總經理持有股份:0股

康樂生技的男性膠原蛋白飲

F-康樂Q1獲利年增43%EPS0.79元(自立電子報2012/04/26)東南亞美容保健第一品牌康樂生技(4154)發佈2012年第1季度財報。拜馬來西亞機能性飲料市場穩定成長及Kinohimitsu"木之秘密"進軍印尼市場布局發酵之賜，結算今年第1季度合併營收約新台幣9319萬元，稅後盈餘1721萬元，每股稅後盈餘0.79元。季度營收較去年同期大幅成長43%，稅前獲利年度成長亦達33%，稅後EPS由去年1.1元減少為0.79元，主要是股本由去年同期的1.23億元大幅擴增至上櫃掛牌後2.18億元，獲利因而遭到稀釋。毛利由去年第1季的73%降低至66%，則是因為擴大市場規模，透過代理商進入中國市場，通路成本較馬來西亞自營略高所致。康樂生技結算2012年第1季合併財報，營收為新台幣9319萬元，營業毛利為6172萬元，毛利率66%，營業淨利1989萬元，營業利益率21%，稅前盈餘1808萬元，稅後盈餘1721萬元，每股稅後盈新台幣0.79元。截至2012年3月31日止，公司資本額2.18億元，帳上擁有資產總計4.22億元，較前一年度1.89億元增加123%以上，其中流動資產達3.35億元，帳上現金多達1.94億元。負債總計僅7382萬元，負債比率僅17%，較前一年度24%大幅下降，股東權益約3.48億元，較前一年度1.43億元大幅增加143%。對於第1季的業績成績，康樂生技表示，拜去年第4季上市的男性膠原蛋白飲，及主力產品膠原蛋白飲獲得印尼市場銷售許可開始進入印尼市場所賜，效益逐漸顯現，營收繳出較去年同期大幅成長逾4成的佳績。康樂生技董事會已通過將於6月18日假太平洋商務中心會議室舉行股東大會。展望第2季，康樂生技說，不斷積極拓展新市場，開發新通路並推出新產品，是康樂生技一貫三大方針。在馬來西亞方面，繼年初在馬來西亞簽約香港知名電視台當家花旦楊怡擔任新代言人後，目前正緊鑼密鼓地進入新產品最後上市前的準備階段，相信未來新產品配合新代言人的高人氣下，將可望再引爆一波"木之秘密"的新產品旋風。另外，康樂生技也在不停地擴增在印尼的通路，由於美容保健機能性飲品在印尼仍是非常創新的商品，康樂生技與其經銷商正計劃許多的產品體驗會及活動等，並通過各種傳媒來教育印尼的消費者Kinohimitsu"木之秘密"商品的獨特性及其功效。康樂生技不吝於投資在品牌的建立上，因為我們相信致力於建立Kinohimitsu"木之秘密"的品牌形象及拓展通路，在這中產階級快速增加的印尼市場，將會是康樂生技的另一個主要市場。

Phalanx Biotech Group Announces CytoOneArray(R), a Targeted Chromosomal Microarray

  May 8, 2012  BELMONT, Calif., May 8, 2012 /PRNewswire via COMTEX/ -- Phalanx Biotech Group, a global genomic products and service provider, announces today the completion of manufacturing and testing for a proprietary targeted chromosomal microarray (CMA) designed specifically for prenatal and postnatal detection of microdeletions and microduplications related to a spectrum of congenital disorders, especially developmental and intellectual delay disorders. CytoOneArray® is capable of detecting 264 clinically confirmed disease regions and 41 subtelomere regions.   "Extensive testing from our CytoOneArray® manufacturing campaign demonstrates a quality product with high sensitivity, robustness, and reproducibility. We are extremely excited about offering our focused CMA at the time when cytogeneticists are adopting chromosomal microarray as a first-tier clinical diagnostic test," said Shengwan Lee, Ph.D., President and CEO. "As the first in a series of CMA microarrays, Phalanx will continue to expand its line of clinical diagnostic products by leveraging its high performance microarray technology and innovative manufacturing processes."   CytoOneArray® resulted from extensive collaborations between leading cytogeneticists in Taiwan and Phalanx Biotech Group. Through a comprehensive curation process of current, peer-reviewed and clinically confirmed disease regions, the Phalanx team designed probes to cover 90% of published microdeletions and microduplications associated with developmental and intellectual delay disorders.   

About Phalanx Biotech Group   Phalanx Biotech Group, with operations in California, Taiwan and China, provides genomics research products and services worldwide to academic, clinical, pharmaceutical and biotech communities. Built on world-class, integrated-chip foundry technology, Phalanx Biotech has developed the OneArray® line of high-quality and affordable microarrays for expression profiling of whole genomes (human, mouse, rat, yeast and rice), microRNA (human, mouse, rat and plants), and custom targets. Our highly-trained service specialists provide a comprehensive offering of gene expression and microRNA expression profiling services for biomarker discovery including sample preparation, expression analysis, and qPCR validation. For more information about our products and services, please visit our website at www.OneArray.com .   ContactVivien Mak, Ph.D., 1-650-320-8669 ext 103vmak@onearray.com   SOURCE Phalanx Biotech Group  

Enzon Pharmaceuticals and Zhejiang Hisun Pharmaceuticals announced a long-term strategic research, development and licensing collaboration.

-(Marketwire - May 7, 2012) -The agreement provides for the research and development of therapeutics using Enzon's customized PEGylation linker technology. The agreement also includes the license to Hisun of development and commercialization rights for Enzon's PEG-SN38 (EZN-2208), a novel, Phase II PEGylated version of SN38, in the territory of China.  Under the terms of the strategic research, development and licensing collaboration, Hisun will pay Enzon to apply its Customized PEGylation Linker Technology, especially its releasable PEGylation technology, and know-how to the development of next-generation, PEGylated versions of select therapeutic candidates within Hisun's pipeline. Once successfully PEGylated, Hisun will have the option to in-license the product candidates, based upon internal selection criteria, and will be fully responsible for funding development and commercialization of these products in the territory of China. Under this agreement, Enzon is entitled to milestone payments and a high-single-digit royalty on net sales for any product developed and commercialized in China, in addition to retaining rights to all PEGylated compounds outside of China.   Hisun has also acquired exclusive development and commercialization rights to PEG-SN38 in China and will pay Enzon an undisclosed upfront fee, milestone payments and a high-single-digit royalty on net sales. Further financial terms were not disclosed. PEG-SN38 has completed Phase II clinical trials in the United States where it was studied as a treatment for metastatic breast cancer, colorectal cancer and solid tumors in pediatric cancer patients. It is a PEGylated conjugate of SN38, the active metabolite of the widely used anti-cancer drug irinotecan. PEG-SN38 offers therapeutic advantages over unmodified SN38, including increased solubility, higher exposure and tumor accumulation, more profound deoxyribonucleic acid (DNA) damage, inhibition of angiogenesis and longer apparent half-life of SN38 as compared to irinotecan.   "Hisun is a dynamic company with an aggressive strategy for expanding its portfolio of innovative therapeutics. We are very excited about this partnership and we look forward to advancing a variety of next-generation therapeutics with Hisun in China and for Enzon in other territories around the world," said Ana Stancic, Principal Executive Officer of Enzon. "Enzon's broad portfolio of proprietary permanent and releasable PEGylation linker technology and decades of know-how offer unmatched, clinically and commercially validated capabilities for the enhancement of existing therapies to create novel, high-value product candidates, including bio-betters."   Hua Bai, CEO and Chairman of Hisun, added, "Enzon's PEGylation technology is utilized in approved products generating a combined total of over $7 billion in annual sales, making them the partner of choice for validated PEGylation technology. In addition to obtaining rights to PEG-SN38, this partnership provides Hisun access to innovative technology and development capabilities that will allow us to deliver novel therapeutics to the rapidly growing pharmaceutical market in China."  Enzon is actively pursuing strategic partnerships with leading biotechnology and pharmaceutical companies worldwide whose marketed, development, or discovery-stage products may benefit from the enhanced pharmaceutical properties of PEGylation. "Our PEGylation platform, combined with our extensive know-how, continues to be the gold standard for maximizing the therapeutic potential of both small molecules and biologics," says Ms. Stancic.   

About Enzon's Customized PEGylation Linker Technology   PEGylation has successfully been used on various pharmaceutical compounds, including enzymes, peptides and antibodies, to improve their pharmaceutical properties through the chemical attachment of polyethylene glycol (PEG) using our Customized Linker Technology. PEGylation technology employs proprietary chemical linkers designed to either release the native molecule at a controlled rate or provide permanent linkage that will maximize inherent activity of the native molecule. In some cases, PEGylation can render a compound therapeutically effective, whereas the unmodified form had only limited clinical utility.   

About Hisun   Hisun is a leading biopharmaceutical group focused on improving patient wellbeing and quality of life. Headquartered in Taizhou (Zhejiang, China), the company currently employs more than 3,800 people. Hisun's operations strictly follow cGMP and received ISO 14000 certification in 2001. To date, more than 40 of the company's products have passed certification by the FDA (US), EDQM (EU), TGA (Australia), KFDA (Korea), etc., and are sold in more than 30 countries. The company opened its U.S. headquarters in Princeton, N.J., in 2010. For more information, visit www.hisunusa.com.  

About Enzon, Inc.   Enzon Pharmaceuticals, Inc. is a biotechnology company dedicated to the research and development of innovative therapeutics for patients with high unmet medical need. Enzon's drug-development programs utilize two platforms: Customized PEGylation Linker Technology (Customized Linker Technology®) and third-generation mRNA-targeting agents utilizing the Locked Nucleic Acid (LNA) technology. Enzon currently has four compounds in human clinical development and multiple novel mRNA antagonists in preclinical research. Enzon receives royalty revenues from licensing arrangements with other companies related to sales of products developed using its proprietary Customized Linker Technology. Further information about Enzon and this press release can be found on the Company's website at www.enzon.com.